www.merckvaccines.com Open in urlscan Pro
192.0.66.224 Public Scan

Back to summary

URL:
https://www.merckvaccines.com/pneumovax23/cdc-acip-recommendation/pneumococcal-vaccine-age-65/2019-update/?utm_source=sfmc&utm...
Submission: On November 11 via api (November 11th 2021, 3:34:22 pm UTC) from US — Scanned from DE

Form analysis
0 forms found in the DOM

Text Content

Menu Close
* Sign In
* Register
* My Profile
* Ordering

* View Products
* BCG Vaccine U.S.P.
* ERVEBO®(Ebola Zaire Vaccine, Live)
* GARDASIL®9(Human Papillomavirus 9-valent Vaccine, Recombinant)
* M-M-R®II(Measles, Mumps, and Rubella Virus Vaccine Live)
* PedvaxHIB®[Haemophilus b Conjugate Vaccine (Meningococcal Protein
Conjugate)]
* PNEUMOVAX®23(Pneumococcal Vaccine Polyvalent)
* ProQuad®(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
* RECOMBIVAX HB®[Hepatitis B Vaccine (Recombinant)]
* RotaTeq®(Rotavirus Vaccine, Live, Oral, Pentavalent)
* VAQTA®(Hepatitis A Vaccine, Inactivated)
* VARIVAX®(Varicella Virus Vaccine Live)
* VAXELIS™(Diphtheria and Tetanus Toxoids and Acellular Pertussis,
Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)
* VAXNEUVANCE™(Pneumococcal 15-valent Conjugate Vaccine)
* Tools & Resources
* Tools & Resources Overview
* Vaccine AdministrationPrepare for vaccine administration, including storage
and handling information.
* Vaccination StrategiesGuide your vaccination process with ideas for
improvement.
* Health Information TechnologyUtilize electronic health record (EHR)
capabilities to help improve vaccination rates.
* Pharmacy SupportExpand year-round vaccination efforts with these resources,
videos, and tools.
* Patient SupportHelp support your patients with informational materials and
office tools.
* ReimbursementIdentify product codes and reimbursement information.
* Medical EducationView our current offerings.
* Disease Information
* Help
* Help Home
* My Profile and Account
* Placing an Order
* My Product Lists
* Order History
* Payments
* Complimentary Materials
* Reporting Adverse Experiences
* DSCSA
* Contact Us
* Ordering

Phone: 877.VAX.MERCK
(877.829.6372)

More contact options

ARE YOU A HEALTH CARE PROFESSIONAL?

This section contains information intended for health care professionals in the
United States only and is not intended for the general public.

No, I am not. Please take me back.

Yes, I am.

This site is intended only for residents of the United States, its territories,
and Puerto Rico. Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc.

+
* Prescribing Information
* Patient Product Information
* Order PNEUMOVAX 23

INDICATION FOR PNEUMOVAX 23

PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention
of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1,
2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20,
22F, 23F, and 33F).
PNEUMOVAX 23 Menu
* VideoPNEUMOVAX 23
* VideoDosage and Administration
* VideoHow Supplied/Storage and Handling
* VideoEfficacy
* Video Select Safety Information
* Pneumococcal Serotypes
* VideoCDC Recommendations
* VideoPatients 65 and Older
* VideoPatients Under 65
* VideoReimbursement Information
* VideoPNEUMOVAX 23 Resources
* VideoFor Your Practice
* VideoFor Pharmacists
* VideoDisease Information
* VideoPatient Website
* Video Frequently Asked Questions

CDC PNEUMOCOCCAL RECOMMENDATIONS FOR ADULTS 65+

Video Player is loading.
Play Video
Play
Mute

Current Time 0:00
/
Duration 10:13
Loaded: 1.63%

00:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -10:13
1x
Playback Rate

Chapters
* Chapters

Descriptions
* descriptions off, selected

Captions
* captions settings, opens captions settings dialog
* captions off, selected

Audio Track
* default, selected

Picture-in-PictureFullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque
Font Size50%75%100%125%150%175%200%300%400%Text Edge
StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional
Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall
Caps
Reset restore all settings to the default valuesDone
Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or
activating the close button.

Dr. Javeed Siddiqui shares the November 2019 CDC recommendation for pneumococcal
vaccination and how you can help protect your patients ages 65+.

Return to CDC Pneumococcal Vaccination Recommendations for Adults Ages 65+

VIDEO TRANSCRIPT | CDC 2019 RECOMMENDATIONS FOR PNEUMOCOCCAL VACCINATION

Voice-Over:

This presentation has been created and paid for by Merck Sharp & Dohme Corp, a
subsidiary of Merck & Co., Inc.

Dr. Siddiqui:

You may have heard that the Centers for Disease Control and Prevention updated
their pneumococcal disease recommendations for adults ages 65 years and older in
November of 2019.

I’m Dr. Siddiqui, an infectious disease physician and Chief Medical Officer at
TeleMed2U in Roseville, CA, and I am here today to talk to you about this
update.

There are 2 kinds of pneumococcal vaccines available for use in adults in the
United States: PNEUMOVAX®23, Pneumococcal Vaccine Polyvalent, and Prevnar 13.
The use of both vaccines in adults ages 65 years and older is discussed in the
CDC recommendations.

Voice-Over:

But first, let’s discuss Indications for PNEUMOVAX 23. PNEUMOVAX 23 is a vaccine
indicated for active immunization for the prevention of pneumococcal disease
caused by the 23 serotypes contained in the vaccine. PNEUMOVAX 23 is approved
for use in persons 50 years of age or older and persons aged 2 years and older
who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not
prevent disease caused by capsular types of pneumococcus other than those
contained in the vaccine.

Dr. Siddiqui:

The CDC continues to recommend routine vaccination with PNEUMOVAX 23 for all
appropriate adults ages 65 years and older. In 2019, the CDC modified its
recommendations for use of Prevnar 13 in adults ages 65 years and older. Prevnar
13 is no longer recommended for routine administration to all immunocompetent
adults in this age group. Instead, for Prevnar 13, the CDC recommends shared
clinical decision-making for certain adults ages 65 years and older who have not
previously received that vaccine. We’ll talk more about this change.

Voice-Over:

Now, let’s discuss some Select Safety Information for PNEUMOVAX 23, which you’ll
hear more of throughout this video. Do not administer PNEUMOVAX 23 to
individuals with a history of a hypersensitivity reaction to any component of
the vaccine. Defer vaccination with PNEUMOVAX 23 in persons with moderate or
severe acute illness. Use caution and appropriate care in administering
PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or
pulmonary function in whom a systemic reaction would pose a significant risk.
Since elderly individuals may not tolerate medical interventions as well as
younger individuals, a higher frequency and/or a greater severity of reactions
in some older individuals cannot be ruled out. Persons who are
immunocompromised, including persons receiving immunosuppressive therapy, may
have a diminished immune response to PNEUMOVAX 23.

Dr. Siddiqui:

To understand the November 2019 updates to the CDC recommendation for
pneumococcal vaccination in adults ages 65 years and older, let us first look at
the history of the previous recommendations for this age group.

In the 1980s, PNEUMOVAX 23 was approved by the FDA, and was recommended by the
CDC for adults ages 65 years and older.

Prevnar 13 was FDA approved for use in older adults in 2011, and in 2014, the
CDC recommended routine vaccination with Prevnar 13 for immunocompetent adults
ages 65 years and older followed by a routine dose of PNEUMOVAX 23.

The CDC stated that the dose of PNEUMOVAX 23 should be given at least one year
after the dose of Prevnar 13. The CDC made this recommendation with the
commitment to reevaluate the use of Prevnar 13 in this population.

Since then, the CDC has been reevaluating direct and indirect effects of Prevnar
13 in adults ages 65 years and older, given the remaining disease burden. In
November 2019, the CDC updated its recommendations for immunocompetent adults
ages 65 years and older.

Let’s discuss the CDC’s rationale for this change.

The CDC observed no population level impact on Prevnar 13-type invasive
pneumococcal disease incidence, as shown in this graph. As well, there was no
observed reduction in incidence of non-invasive pneumococcal pneumonia during
this time. As stated in the CDC’s official publication of its updated
pneumococcal recommendations, routine vaccination with a single dose of
PNEUMOVAX 23 continues to be recommended for all appropriate adults ages 65
years and older.

However, the use of Prevnar 13 in certain patients ages 65 years and older–
specifically, those who do not have an immunocompromising condition,
cerebrospinal fluid, or CSF leak, or cochlear implant, and who have not
previously received Prevnar 13 – is based on shared clinical decision making.
Unlike a routine recommendation, shared clinical decision-making recommendations
are individually-based and informed by a decision process between the health
care provider and the patient.

When these patients and their vaccine providers engage in shared clinical
decision-making about the option to use Prevnar 13, considerations may include
the individual patient’s risk of exposure to Prevnar 13 serotypes and the risk
for pneumococcal disease for that person as a result of underlying medical
conditions.

Voice-Over:

Here is some additional safety information for PNEUMOVAX 23. PNEUMOVAX 23 may
not be effective in preventing pneumococcal meningitis in patients who have
chronic cerebrospinal fluid leakage resulting from congenital lesions, skull
fractures, or neurosurgical procedures.

Dr. Siddiqui:

Let’s discuss intervals for sequential administration if you decide to vaccinate
appropriate immunocompetent patients ages 65 and older with Prevnar 13. For
pneumococcal vaccine-naïve patients ages 65 years and older who receive Prevnar
13 based on shared clinical decision making, it is important for the patient to
also receive 1 dose of PNEUMOVAX 23 at least 1 year later because PNEUMOVAX 23
remains routinely recommended for these patients. Importantly, for
immunocompetent adults in whom the 2014 sequential regimen was initiated with
Prevnar 13 but not yet completed with PNEUMOVAX 23, one dose of PNEUMOVAX 23
should be routinely administered at least 1 year after Prevnar 13 was given.

For those who previously received PNEUMOVAX 23 before the age of 65 years, for
example, those with certain chronic conditions such as diabetes, for whom
PNEUMOVAX 23 is recommended, an additional dose of PNEUMOVAX 23 should be
administered when they reach the age of 65, given at least 5 years after their
first PNEUMOVAX 23 dose.

Please note these important considerations regarding sequential administration.
There are limited data on the sequential administration of PNEUMOVAX 23 with
other vaccines, including Prevnar 13. An immunogenicity study described in the
Prescribing Information for Prevnar 13 evaluated the sequential administration
with PNEUMOVAX 23 in adults ages 60 to 64 years:

* Diminished immune response with one dose of PNEUMOVAX 23 followed by a dose
of Prevnar 13 one year later vs Prevnar 13 alone
* Noninferior immune response with one dose of Prevnar 13 followed by a dose of
PNEUMOVAX 23 one year later vs PNEUMOVAX 23 alone

The levels of antibodies that correlate with protection against pneumococcal
disease have not been clearly defined. Routine revaccination of immunocompetent
persons previously vaccinated with a 23-valent vaccine is not recommended. For
subjects ages 65 years or older in a clinical study, systemic adverse reactions
which were determined by the investigator to be vaccine-related were higher
following revaccination with PNEUMOVAX 23 than following initial vaccination
with PNEUMOVAX 23. PNEUMOVAX 23 contains 11 unique pneumococcal serotypes not
contained in Prevnar 13 and 12 shared serotypes with Prevnar 13.

Voice-Over:

Let’s again discuss some safety information for PNEUMOVAX 23. The most common
adverse reactions, reported in more than 10% of subjects vaccinated with
PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness,
injection-site swelling/induration, headache, injection-site erythema, asthenia
and fatigue, and myalgia. Vaccination with PNEUMOVAX 23 may not offer 100%
protection from pneumococcal infection.

Dr. Siddiqui:

Despite CDC recommendations for pneumococcal vaccination for adults ages 65
years and older, pneumococcal vaccination rates in this population remain
suboptimal. Based on a CDC analysis of certain pneumococcal vaccination claims
submitted for reimbursement to the Centers for Medicare and Medicaid Services,
as of September 2017 approximately 57% of adults ages 65 years and older had not
received PNEUMOVAX 23, as recommended by the CDC. We can make a positive impact
for our patients by doing all we can today to help protect them against
pneumococcal disease.

ref1

Reference

1. Centers for Disease Control and Prevention (CDC). Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide
vaccine among adults aged ≥65 years: Updated recommendations of the Advisory
Committee on Immunization Practices. MMWR. 2019;68(46):1069–1075.

INDICATION FOR PNEUMOVAX 23

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for
active immunization for the prevention of pneumococcal disease caused by the 23
serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A,
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons
aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus
other than those contained in the vaccine.

SELECT SAFETY INFORMATION FOR PNEUMOVAX 23

Do not administer PNEUMOVAX 23 to individuals with a history of a
hypersensitivity reaction to any component of the vaccine.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute
illness.

SELECT SAFETY INFORMATION FOR PNEUMOVAX 23

Do not administer PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) to individuals
with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute
illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals
with severely compromised cardiovascular and/or pulmonary function in whom a
systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not
established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as
younger individuals, a higher frequency and/or a greater severity of reactions
in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive
therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in
patients who have chronic cerebrospinal fluid (CSF) leakage resulting from
congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with
PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site
pain/soreness/tenderness, injection-site swelling/induration, headache,
injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse
reactions which were determined by the investigator to be vaccine-related were
higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal
infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing
Information. The Patient Information also is available.

INDICATION FOR PNEUMOVAX 23

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons
aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus
other than those contained in the vaccine.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

https://www.vaxelis.com

CANCEL
CONTINUE

Thank you for visiting.

--------------------------------------------------------------------------------

US-PNX-02162 08/21

HELPFUL LINKS

* Supply Status
* Prime Distributors
* Return Merchandise
* Shipping Schedule
* Storage and Handling
* Disaster Relief Returns Program
* Packaging Information Guide
* DSCSA T3 Data
* Ordering
* Informational Links
* Terms & Conditions of Sale
* Reimbursement Codes

Show MoreLess

You are about to leave MerckVaccines.com.

Cancel Continue

Thank you for visiting MerckVaccines.com®

A service brought to you by Merck & Co., Inc.

Merck does not review or control the content at the site to which this link
connects. Merck makes no representation with respect to the content of any
non-Merck site.

Additional Merck Sites:

* My Merck Accounts
* MerckConnect
* Merck Helps

Phone: 877.VAX.MERCK
(877.829.6372)

More contact options

* Privacy Policy
* Terms of Use
* Site Map
* Cookie Preferences

This site is intended for health care professionals in the United States, its
territories, and Puerto Rico.

PRIVACY PREFERENCE CENTER

YOUR PRIVACY

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information

* STRICTLY NECESSARY COOKIES

STRICTLY NECESSARY COOKIES

Always Active
Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be
switched off in our systems. They are usually only set in response to actions
made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your
browser to block or alert you about these cookies, but some parts of the site
will not then work. These cookies do not store any personally identifiable
information.

Cookies Details‎

* FUNCTIONAL COOKIES

FUNCTIONAL COOKIES

Always Active
Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. The cookies ensure that these services
function properly.

Cookies Details‎

* PERFORMANCE COOKIES

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure
and improve the performance of our site. They help us to know which pages are
the most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If
you do not allow these cookies we will not know when you have visited our
site, and will not be able to monitor its performance.

Cookies Details‎

* TARGETING COOKIES

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They
may be used by those companies to build a profile of your interests and show
you relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Cookies Details‎

Back Button

ADVERTISING COOKIES

Filter Button
Consent Leg.Interest
Select All Vendors
Select All Vendors
Select All Hosts

Select All

* REPLACE-WITH-DYANMIC-HOST-ID

View Third Party Cookies

* Name
cookie name

Clear Filters

Information storage and access
Apply
Confirm My Choices Accept All Cookies

This Site Uses Cookies and Your Privacy Choice Is Important to Us
We suggest you choose Customize My Settings to make your individualized choices.
Accept All Cookies means that you are choosing to accept third-party Cookies and
that you understand this choice. See our Privacy Policy

Customize My Settings Accept All Cookies

www.merckvaccines.com Open in urlscan Pro 192.0.66.224 Public Scan

Form analysis 0 forms found in the DOM

Text Content

www.merckvaccines.com Open in urlscan Pro
192.0.66.224 Public Scan

Form analysis
0 forms found in the DOM